GMED vs SLS
Globus Medical vs SELLAS Life Sciences Group, Inc. — AI-powered side-by-side comparison
GMED
Globus Medical
71
Buy
VS
SLS
SELLAS Life Sciences Group, Inc.
57
Watch
| Metric | GMED | SLS |
|---|
| AI Score |
71
|
57
|
| Price |
$85.12
|
$11.03
|
| P/E Ratio |
21.45×
|
-52.30×
|
| ROE |
11.8%
|
-37.9%
|
| Revenue Growth YoY |
—
|
—
|
| Gross Margin |
68.5%
|
0.0%
|
| Debt / Equity |
0.02×
|
0.01×
|
| Dividend Yield |
0.0%
|
0.0%
|
| RSI (14) |
75.9
|
43.9
|
| Beta |
0.954
|
2.494
|
| Expected Upside |
+0.1%
|
—
|
AI Committee View
Current Innellis committee reasoning for GMED versus SLS.
GMED leads by 14 points.
GMED scores 71/100 (Buy) versus SLS at 57/100 (Watch).
GMED Committee View
75% agreement
4 analysts
The primary driver is 5 consecutive earnings beats -- consistent execution. The main limiting factor is rsi at 76 is in overbought territory. The committee is constructive but not yet at full conviction.
Bull Case
- 5 consecutive earnings beats -- consistent execution — Growth
- Quarter-over-quarter growth rate is ACCELERATING, not just positive — Growth
- MACD histogram positive -- bullish momentum — Technical
Bear Case
- RSI at 76 is in overbought territory — Technical
- Price trading above the upper Bollinger Band -- stretched — Technical
SLS Committee View
80% agreement
5 analysts
Some positive signals exist — vix regime is low -- calm backdrop supports risk-taking — but they are not yet strong enough to justify a Buy. The committee is monitoring for confirmation.
Bull Case
- Low leverage (debt-to-equity 0.00) -- balance sheet can absorb a shock — Risk
- VIX regime is low -- calm backdrop supports risk-taking — Macro
- Market regime is bullish (Bull market -- normal position sizing) — Macro
Bear Case
- Price-to-book of 7.6x prices in significant intangible value — Value
- ROE of only -47.1% -- cheap may mean cheap for a reason — Value
- MACD histogram negative -- bearish momentum — Technical